The nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients

Transplantation

Volumn 63, Issue 11, 1997, Pages 1591-1594

  Keiding, Susanne ^a   Höckerstedt, Krister ^b   Bjøro, Kristian ^c   Bondesen, Stig ^d   Hjortrup, Allan ^d   Isoniemi, Helena ^b   Erichsen, Christian ^c   Söderdahl, Gunnar ^e   Ericzon, Bo Göran ^e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GAMMA GLUTAMYLTRANSFERASE; METHYLPREDNISOLONE; OKT 3; PLACEBO; PREDNISOLONE; STEROID; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHOLESTASIS; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NASOGASTRIC TUBE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 0342762045     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199706150-00009     Document Type: Article

References (17)

1. Persson H, Friman S, Scherstén T, Svanvik J, Karlberg I. Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients [Letter], Lancet 1990; 336: 52.
2. Pageaux GP, Blanc P, Perrigault PF, et al. Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation. J Hepatol 1995; 23: 119.
3. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149.
4. Beuers S, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1990; 13: 707.
5. Poupon RE, Balkau B, Eschwège E, Poupon R, UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548.
6. Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268.
7. Poupon RE, Balkau B, Poupon R. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330: 1342.
8. Rafael E, Duraj FE, Rudström H, Wilczek HE, Ericzon BG. Effect of ursodeoxycholic acid treatment for cholestasis in liver transplant recipients. Transplant Proc 1995; 27: 3501.
9. Snover DC, Freese DK, Sharp HL, Bloomer JR, Najarian JS, Ascher NL. Liver allograft rejection: an analysis of the use of biopsy in determining outcome of rejection. Am J Surg Pathol 1986; 11: 1.
10. EEC Note for Guidance. Good clinical practice for trials on medicinal products in the European community. Pharmacol Toxicol 1990; 67: 361.
11. Pratt DS, Kaplan MM. Abdominal pain after taking ursodiol [Letter]. N Engl J Med 1993; 328: 1502,
12. Al-Quaiz MN, O'Grady JG, Tredger JM, Williams R. Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. Transpl Int 1994; 7: 190.
13. Marteau P, Chazouilléres O, Myara A, Jian R, Rambaud J, Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1990; 12: 1206.
14. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990; 12: 486.
15. Krähenbühl S, Fischer S, Talos C, Reichen J. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. Hepatology 1994; 20: 1595.
16. Yoshikawa M, Tsujii T, Matsumura K, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16: 358.
17. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11: 12.